L-Serine-d7
(Synonyms: L-丝氨酸-D7,(-)-Serine-d7; (S)-Serine-d7) 目录号 : GC49461
An internal standard for the quantification of L-serine
Cas No.:935275-35-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
L-Serine-d7 is intended for use as an internal standard for the quantification of L-serine by GC- or LC-MS. L-Serine is a non-essential amino acid.1 It is produced from 3-phosphoglycerate in a multistep biosynthesis catalyzed by phosphoglycerate dehydrogenase (PGDH), phosphoserine aminotransferase (PSAT), and phosphoserine phosphatase (PSP). L-Serine can also be derived from dietary sources, as well as protein and phospholipid turnover. Defective L-serine biosynthesis is associated with neural tube defects and deoxysphingolipid accumulation in patients with Neu-Laxova syndrome, a rare disease characterized by a mutation in PGDH.1,2 Dysregulation of L-serine phosphorylation is associated with disease progression in patients with neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis.
1.Holm, L.J., and Buschard, K.L-serine: A neglected amino acid with a potential therapeutic role in diabetesAPMIS127(10)655-659(2019) 2.Metcalf, J.S., Dunlop, R.A., Powell, J.T., et al.L-serine: A naturally-occurring amino acid with therapeutic potentialNeurotox. Res.33(1)213-221(2018)
| Cas No. | 935275-35-7 | SDF | Download SDF |
| 别名 | L-丝氨酸-D7,(-)-Serine-d7; (S)-Serine-d7 | ||
| Canonical SMILES | [2H]OC([C@](N([2H])[2H])([2H])C([2H])([2H])O[2H])=O | ||
| 分子式 | C3D7NO3 | 分子量 | 112.1 |
| 溶解度 | Water: soluble | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 8.9206 mL | 44.603 mL | 89.2061 mL |
| 5 mM | 1.7841 mL | 8.9206 mL | 17.8412 mL |
| 10 mM | 0.8921 mL | 4.4603 mL | 8.9206 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。